Alzheimer’s Treatment

IHS's intranasal dual gene therapy, utilizing a telomerase inducer and klotho, has demonstrated promising benefits for patients with dementia and Alzheimer's disease. In a study of five patients with mild to moderate dementia, cognitive function improved significantly following treatment. Initial Folstein testing scores ranged from 13 to 26, with a notable increase during the first three and a half months post-treatment, averaging a 1.7-point improvement per month. Although there was a slight decline in scores afterward, the overall cognitive enhancement remained stable for over a year. This suggests that the therapy has the potential to enhance cognitive function and slow disease progression in affected individuals.

The treatment's positive impact on telomere length further supports its potential for neuroprotection and longevity. Telomere shortening is associated with cellular aging, inflammation, and increased disease risk. In this study, telomere length improved in four out of five patients, with a statistically significant increase in the 20th percentile group, indicating potential cellular rejuvenation. The biological age of participants also decreased post-treatment, reinforcing the idea that telomerase induction can counteract age-related decline. These findings suggest that the therapy may provide long-term benefits by enhancing cellular resilience and reducing neurodegeneration.

Klotho, a crucial component of this gene therapy, is known for its neuroprotective properties. It has been linked to enhanced synaptic plasticity, reduced oxidative stress, and improved cognitive function. The study showed a rapid cognitive boost within the first quarter post-treatment, which aligns with klotho's known role in promoting neuronal health. By combining klotho expression with telomerase activation, the therapy offers a multifaceted approach to combating neurodegenerative diseases, addressing both immediate cognitive decline and the underlying mechanisms of aging.

The study also demonstrated the safety of IHS's intranasal gene therapy. No significant adverse effects, immune responses, or laboratory abnormalities were observed throughout the follow-up period. Brain MRI scans revealed no detectable structural changes or negative impacts, further supporting the therapy’s safety profile. The treatment was well-tolerated, with minimal discomfort, making it a viable option for elderly patients who may be vulnerable to more invasive procedures. This safety data strengthens the case for broader clinical application and further studies to validate long-term efficacy.

Our technology and care, your healthy longevity:

IHS is dedicated to providing you with the latest breakthroughs in medical technologies to help you at this difficult time in your life. Our doctors are here to help you every step of the way. To schedule your 20 minutes consultation with a doctor from Integrated Health Systems, please click